Loading...
XNASRVNC
Market cap353mUSD
Jan 08, Last price  
3.39USD
1D
-0.59%
1Q
-35.55%
Jan 2017
-83.62%
IPO
-87.89%
Name

Revance Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:RVNC chart
P/E
—
P/S
1.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.52%
Rev. gr., 5y
128.84%
Revenues
234m
+76.55%
557,000717,000617,000383,000300,000300,000262,0003,729,000413,00015,325,00077,798,000132,565,000234,040,000
Net income
-324m
L-9.10%
-44,863,000-58,259,000-52,448,000-62,917,000-73,476,000-89,270,000-120,587,000-142,568,000-156,217,000-282,089,000-286,824,000-356,422,000-323,986,000
CFO
-217m
L+11.90%
-28,413,000-38,914,000-47,758,000-55,073,000-55,669,000-59,827,000-95,342,000-104,246,000-106,161,000-178,502,000-221,538,000-193,548,000-216,575,000
Earnings
Feb 26, 2025

Profile

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
URL
https://www.revance.com/
IPO date
Feb 06, 2014
Employees
534
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
234,040
76.55%
132,565
70.40%
Cost of revenue
523,811
340,292
Unusual Expense (Income)
NOPBT
(289,771)
(207,727)
NOPBT Margin
Operating Taxes
300
700
Tax Rate
NOPAT
(290,071)
(208,427)
Net income
(323,986)
-9.10%
(356,422)
24.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
100,183
241,518
BB yield
-13.47%
-17.99%
Debt
Debt current
10,854
4,912
Long-term debt
516,919
452,650
Deferred revenue
70,419
78,577
Other long-term liabilities
2,835
1,485
Net debt
266,988
110,803
Cash flow
Cash from operating activities
(216,575)
(193,548)
CAPEX
(6,886)
(23,010)
Cash from investing activities
109,740
(138,798)
Cash from financing activities
136,567
331,694
FCF
(319,103)
(207,181)
Balance
Cash
253,915
340,707
Long term investments
6,870
6,052
Excess cash
249,083
340,131
Stockholders' equity
(2,078,258)
(1,754,666)
Invested Capital
2,478,342
2,265,796
ROIC
ROCE
EV
Common stock shares outstanding
84,599
72,713
Price
8.79
-52.38%
18.46
13.11%
Market cap
743,629
-44.60%
1,342,288
21.83%
EV
1,010,617
1,453,091
EBITDA
(276,078)
(168,581)
EV/EBITDA
Interest
19,356
16,474
Interest/NOPBT